Bactazon is an antibacterial agent used for conditions associated with acute or disruptive episodes in clinical settings. Its purpose is to provide supportive therapeutic benefit in addressing conditions presenting with systemic or localized discomfort, relevant when symptoms are linked to antibiotic resistance. In this context, its use is considered relevant in multiple key therapeutic areas.

---

The medication is commonly used across therapeutic domains involving conditions characterized by periods of heightened symptoms, such as septicemia (blood infections), lower respiratory tract infections like pneumonia, and intra-abdominal infections (e.g., peritonitis). It is also relevant for addressing infections of the skin, soft tissues, bones, and joints. This is often applied in addressing infections that may be difficult to manage—those that are not responsive to many standard treatments.

Focus on Symptom Relief

The treatment may assist with managing symptoms related to systemic imbalance, such as high fever, chills, and profound fatigue. This symptomatic support contributes to easing the overall symptom load.

---

Quick Fact: Support for Systemic Imbalance Symptoms

Regulatory References

1. WHO EML Expert Committee on AMR/AWaRe Classification

Eligibility Map: Who can and cannot use Bactazon — official regulatory information

Eligibility scope	Details (Strictly from Regulatory Documents)
Populations for whom use is allowed (as stated in label):	Adults (Standard labeled population). Children and Infants (Has been effectively used). Elderly Patients (Permitted, but requires caution due to potential age-related organ dysfunction).
Populations for whom use is not recommended (if applicable):	Premature Infants and Neonates: Use is not extensively studied and requires considering potential risks and benefits.
Populations for whom use is contraindicated:	Patients with a known history of hypersensitivity (allergy) to Cefoperazone, Sulbactam, penicillins, or any other cephalosporin antibiotic.
Age-related eligibility rules:	Neonates in the first week of life require a specific administration frequency. Infants, especially premature infants, require periodic organ system monitoring during extended therapy.
Condition-specific eligibility rules:	Severe Hepatic Disease / Biliary Obstruction: Use is conditional on potential dose modification and monitoring. Renal Dysfunction ( CrCl < 30 mL/min): Use is conditional on an adjustment for the Sulbactam component. Combined Hepatic and Renal Impairment: Requires monitoring of Cefoperazone serum concentrations.
Pregnancy and lactation eligibility status (if explicitly documented):	Pregnancy: Should be used only if clearly needed due to a lack of adequate and well-controlled human studies. Lactation: Caution should be exercised when administered to a nursing mother.
Eligibility-related restrictions:	Patients with Malabsorption States, Poor Diet, or Prolonged IV Alimentation: Requires monitoring of prothrombin time and Vitamin K administration due to risk of deficiency. Patients with History of Alcohol Abuse: Must be cautioned to avoid alcohol during therapy and up to five days after administration.

---

Eligibility classifications (high-level)

Classification/Basis	Details
Eligibility severity classification:	Contraindicated (Hypersensitivity); Conditional/Restricted Use (Renal/Hepatic Impairment, Pregnancy, High-Risk Nutritional Status); Use Not Extensively Studied (Premature Infants).

---

Resulting eligibility structure

Official eligibility statements:

• Use is contraindicated in patients with a known history of allergy to Cefoperazone, Sulbactam, or related antibiotics (penicillins, cephalosporins).
• Eligibility is conditional on assessment and potential adjustment in patients with severe hepatic dysfunction or severe renal dysfunction.
• Use in pregnancy is permitted only if clearly needed due to insufficient data from human studies.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Bactazon by establishing absolute prohibitions based on hypersensitivity, while applying conditional rules for patients whose physiological status, such as organ function or age, affects how the drug is cleared from the body. These constraints are detailed in the official product labeling to ensure that the drug is reserved only for populations where its use is either established or where necessary precautions can be formally implemented.

Interactions with other medicines and products

Official regulatory information addresses several clinically significant interaction domains for Bactazon, particularly concerning its potential for systemic effects.

Interacting Product Category	Official Interaction Classification	Interaction Constraint
Nephrotoxic Agents	Clinically Significant / Major	Co-administration is generally not recommended due to increased risk of additive renal toxicity.
Neuromuscular Blocking Agents	Clinically Significant / Moderate	Potential to prolong neuromuscular blockade; requires close monitoring for signs of respiratory depression.
Oral Anticoagulants	Clinically Significant / Moderate	May potentiate the anticoagulant effect, which necessitates careful and frequent monitoring of coagulation parameters (e.g., INR).
Probenecid	Clinically Significant / Moderate	Reduces the elimination of the active components of Bactazon, leading to higher and more prolonged exposure.

When Bactazon is used systemically, its interaction profile is largely defined by the potential for additive toxicity. Specifically, co-administration with other medications known to cause damage to the kidneys, such as aminoglycosides or certain NSAIDs, is a major concern explicitly noted in regulatory documents and often leads to the requirement for alternative therapy or intensive monitoring of kidney function. The interaction with certain anticoagulants and neuromuscular blockers is classified as clinically significant, demanding careful observation for enhanced effects on clotting or muscle function, respectively. This profile ensures management strategies are in place to mitigate these documented risks.

Targeting the Bacterial Cell Wall Structure

Bactazon utilizes a primary component that acts as a selective, irreversible inhibitor of key bacterial Penicillin-Binding Proteins (PBPs). These enzymes are essential for the final cross-linking step of peptidoglycan synthesis, which forms the bacteria's rigid cell wall. By blocking this process, the structural integrity of the cell wall is compromised. This disruption leads to osmotic instability within the cell and ultimately causes its lysis and death.

---

Overcoming Bacterial beta-Lactamase Enzymes

A second component in Bactazon functions as a specific inhibitor of bacterial beta-lactamase enzymes. These enzymes are produced by some bacteria to chemically inactivate the primary PBP-inhibiting component. By binding to and neutralizing the beta-lactamase, this synergistic mechanism prevents the inactivation of the first component, thereby enabling the full inhibition of PBPs and contributing to the reduction of the viable bacterial population.

How to Use Bactazon: Administration Overview

Bactazon, a fixed-dose combination of Cefoperazone and Sulbactam, is for parenteral use, meaning it is administered by professional healthcare staff via intravenous (IV) or intramuscular (IM) injection. It is supplied as a sterile dry powder and requires reconstitution and subsequent dilution before administration. The standard administration route is IV, delivered either as an injection or an intermittent infusion.

The dosing schedule for adults is typically divided into two equal doses, administered every 12 hours (BID). The usual total daily dose ranges from 2 g to 4 g of the combination, though doses may be increased up to a maximum of 8 g in severe cases, administered intravenously. A key constraint is the maximum recommended daily dose of the Sulbactam component, which is 4 g for adults.

Procedural and Population-Specific Instructions

Procedural Requirement	Standard Guideline
IV Infusion Rate	Administered over a period of 15 to 60 minutes.
Initial Preparation	The powder is reconstituted with compatible diluents (e.g., Sterile Water or 0.9% Sodium Chloride); Lactated Ringer’s Solution is not used for initial mixing.
Renal Impairment	Dose adjustment is utilized for moderate to severe kidney dysfunction (CrCl < 30 mL/min). The maximum daily Sulbactam component is limited to 1 g in severe impairment.
Treatment Duration	Therapy typically ranges from 7 to 14 days, often continuing for at least 48 hours after clinical improvement is demonstrated.

These parameters establish a protocol for the administration of the medicine in clinical settings, facilitating consistent delivery according to established specifications.

Research evidence / Overview of studies for Bactazon

Evidence for Use in Intra-abdominal Infections and Pneumonia

The research base for Bactazon in systemic infections, including the abdomen and lower respiratory tract, relies on systematic reviews and comparative studies. These studies, which feature Randomized Controlled Trials (RCTs) and subsequent meta-analyses, were applied in research contexts involving fluctuating or unstable symptoms typical of acute bacterial conditions. Researchers explored the combination product in clinical research against various comparator antibiotics, focusing on adult and paediatric populations.

Studies monitored key outcomes related to systemic or functional imbalance, such as whether the patient achieved Clinical Cure/Success and the rate of Microbiological Eradication of the causative organism. Studies observed patterns related to clinical outcomes, and reports indicate that measured rates of success were consistent with those observed for various comparator antibiotic regimens.

Evidence for Severe Infections (Empiric and Targeted Use)

The combination product was evaluated in research exploring severe, acute bacterial conditions, which research explored in the context of phases of heightened symptom activity. This includes research examining its use as an empiric therapy for febrile neutropenia and for infections caused by certain multidrug-resistant organisms (MDROs).

Research on Multidrug-Resistant Organisms

Research examined infections caused by difficult bacteria, such as some MDROs, where evidence quality varies. The data for this specific use is largely derived from multicenter retrospective cohort studies and analyses of pooled observational data, rather than prospective RCTs. These studies monitored outcomes linked to inflammatory or irritative states, such as 30-day mortality and measured changes in clinical scores. Research for this specific use is still emerging, and certainty remains low compared to the core indications.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known — and what is still uncertain. One key research limitation is that the appropriate regimen for measured outcomes in all critically ill patients is not fully established. While various studies were conducted during periods of increased symptom activity, the comparative evidence is lacking on different regimens. Research is ongoing to refine the understanding of the product’s use, particularly in the context of treating specific, difficult-to-manage, multidrug-resistant pathogens.

Key Studies & References Proposal to the 2025 WHO EML Expert Committee on AMR/AWaRe Classification regarding Cefoperazone/Sulbactam

Common questions about Bactazon (FAQ)

---

Q: Why is it important to avoid alcohol while I am on Bactazon therapy and for a time afterward?

Regulatory information recommends avoiding alcohol consumption during treatment and for up to five days after the last dose. This restriction is necessary because the drug carries the documented risk of a disulfiram-like reaction, which can cause unpleasant symptoms such as flushing, sweating, and headache.

---

Q: Does the dosage need to be changed for patients who have kidney problems?

Yes, official prescribing guidelines require that the dosage be adjusted for patients with moderate to severe kidney dysfunction. This adjustment primarily concerns the Sulbactam component of the combination. In cases of severe kidney impairment, the maximum recommended daily dose of Sulbactam is limited by clinical guidelines.

---

Q: What is the role of Sulbactam in this combined medicine?

Bactazon contains two active ingredients, and Sulbactam serves a critical function in the combination. Its role is to act as a specific inhibitor against certain bacterial defense enzymes known as beta-lactamases. By neutralizing these enzymes, Sulbactam protects the other active component, Cefoperazone, allowing it to remain effective at fighting the infection.

---

Q: What kind of bacteria is Bactazon most effective against?

The medication is classified as a broad-spectrum systemic antibacterial agent. Official studies indicate that the drug is effective against a variety of susceptible organisms. This includes many clinically significant Gram-negative bacteria, such as E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

---

Q: Is Bactazon a branded or generic medicine, and where is it available (e.g., prescription only, over the counter)?

Bactazon is the brand name for a fixed-dose combination product containing Cefoperazone and Sulbactam. Like most antibiotics, official regulatory classification designates this medicine as a Prescription Drug (Rx). Since it is for injection only, it is typically administered by healthcare professionals in a clinical setting.

---

Q: Can Bactazon be used as a treatment for COVID-19 or any viral infections?

Official prescribing information indicates that Bactazon is classified as a systemic antibacterial agent. It is only approved to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. The medicine does not have an approved indication for the treatment of viral infections, including COVID-19.

---

Q: How long after the powder is mixed can the solution be safely used for injection?

Once the dry powder is mixed, the resulting solution has a limited stability period before it must be administered. Official product information states that solutions stored under refrigeration (between 2 C and 8 C) are typically stable for up to five days. Solutions kept at room temperature remain stable for a shorter period, usually between 24 and 48 hours, depending on the fluid used for mixing.

How to Store and Dispose of Bactazon?

Bactazon (Cefoperazone/Sulbactam) is supplied as a dry powder for injection/infusion, requiring specific storage conditions to maintain its quality.

Storage Requirements

The unreconstituted powder must be stored at Controlled Room Temperature, which is defined as being at or below 25 C (77 F) or not exceeding 30 C. The vials must be protected from light and kept in the outer carton until use. It is a mandatory requirement to store the medicine out of the sight and reach of children.

Stability and Disposal

Once the powder is reconstituted, the solution's stability is limited. Refrigerated solutions (2 C to 8 C) are stable for up to five days, while room temperature solutions are stable for 24 to 48 hours. Refreezing thawed solutions is strictly prohibited.

Any unused or expired product must be disposed of in accordance with local regulations for medicinal waste and must not be discharged into sewer systems.